PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.59M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-3.16%
Negative revenue growth while MCHP stands at 3.90%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-4.91%
Negative gross profit growth while MCHP is at 4.75%. Joel Greenblatt would examine cost competitiveness or demand decline.
133.15%
Positive EBIT growth while MCHP is negative. John Neff might see a substantial edge in operational management.
184.17%
Operating income growth above 1.5x MCHP's 2.58%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
37.12%
Positive net income growth while MCHP is negative. John Neff might see a big relative performance advantage.
39.13%
EPS growth of 39.13% while MCHP is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
39.13%
Positive diluted EPS growth while MCHP is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.54%
Share reduction while MCHP is at 0.46%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.09%
Reduced diluted shares while MCHP is at 5.30%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-0.74%
Dividend reduction while MCHP stands at 0.27%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-66.82%
Negative OCF growth while MCHP is at 25.87%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-72.09%
Negative FCF growth while MCHP is at 20.26%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
98.72%
10Y revenue/share CAGR at 75-90% of MCHP's 129.37%. Bill Ackman would press for new markets or product lines to narrow the gap.
5.70%
5Y revenue/share CAGR under 50% of MCHP's 50.35%. Michael Burry would suspect a significant competitive gap or product weakness.
0.26%
3Y revenue/share CAGR under 50% of MCHP's 72.50%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
177.32%
10Y OCF/share CAGR above 1.5x MCHP's 88.32%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
-32.68%
Negative 5Y OCF/share CAGR while MCHP is at 18.58%. Joel Greenblatt would question the firm’s operational model or cost structure.
-43.52%
Negative 3Y OCF/share CAGR while MCHP stands at 5.94%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
367.16%
Net income/share CAGR 1.25-1.5x MCHP's 276.97%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
-34.45%
Negative 5Y net income/share CAGR while MCHP is 10.52%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-38.72%
Negative 3Y CAGR while MCHP is 171.85%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
54.13%
10Y equity/share CAGR at 50-75% of MCHP's 88.32%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
33.19%
5Y equity/share CAGR above 1.5x MCHP's 10.39%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
24.41%
3Y equity/share CAGR at 75-90% of MCHP's 30.90%. Bill Ackman pushes for margin or operational changes to match the competitor’s pace.
846.73%
Dividend/share CAGR of 846.73% while MCHP is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
109.10%
5Y dividend/share CAGR above 1.5x MCHP's 24.98%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
73.43%
3Y dividend/share CAGR above 1.5x MCHP's 3.30%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
8.37%
AR growth well above MCHP's 2.63%. Michael Burry fears inflated revenue or higher default risk in the near future.
-3.24%
Inventory is declining while MCHP stands at 1.93%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-1.81%
Negative asset growth while MCHP invests at 1.98%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
0.46%
50-75% of MCHP's 0.91%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-0.05%
We’re deleveraging while MCHP stands at 0.65%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-1.41%
Our R&D shrinks while MCHP invests at 2.33%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
6.74%
SG&A growth well above MCHP's 9.53%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.